Free Virtual
Lupus Health Conference
SATURDAY APRIL 08| 11 AM- 2PM
JOIN US VIRTUALLY!
JOIN US VIRTUALLY!
Join us virtually for our 1st Lupus Health Conference of 2023!!
This first session's topic will be "SLE Dx & Rx 2023". During this presentation Dr. C. Michael Neuwelt will discuss Diagnosis Systemic Lupus 2023, Treatment - Non-organ Threatening Disease and New Medication Treatment for Lupus - Biological Treatment 2023 and Beyond.
The second session's topic will be" Bringing Lupus Nephritis out of the Shadows" presented by Dr. Elizabeth Clayton.
This program is FREE to lupus patients, family members, health professionals and other interested parties.
This first session's topic will be "SLE Dx & Rx 2023". During this presentation Dr. C. Michael Neuwelt will discuss Diagnosis Systemic Lupus 2023, Treatment - Non-organ Threatening Disease and New Medication Treatment for Lupus - Biological Treatment 2023 and Beyond.
The second session's topic will be" Bringing Lupus Nephritis out of the Shadows" presented by Dr. Elizabeth Clayton.
This program is FREE to lupus patients, family members, health professionals and other interested parties.
Session 1: Keynote by Dr. C. Michael Newell
Director of Rheumatology CORE Curriculum
St. Mary’s Medical Center, San Francisco, CA
Director of East Bay Rheumatology Research Institute
San Leandro, CA
Dr. Neuwelt has been challenged and fascinated by SLE since 1973 during his third year of medical school. This challenge and interest has persisted throughout his 43 years in clinical private practice which began in 1979.
His original publications involve an observational series and case reports of severe Neuropsychiatric Lupus (NPSLE), including progressive multifocal leukoencephalopathy mimicking NPSLE, and three treatment studies of Severe NPSLE with Cyclophosphamide, Rituximab, and plasmapheresis.
Dr. Neuwelt has extensive experience in B cell-depleting and modulating therapy in SLE, beginning
with cyclophosphamide in 1980, Rituximab in 2002 (second author of negative EXPLORER trial,
Ocrelizumab, Epratuzumab and Tabalumab. He has started over 200 patients on Belimumab
(Benlysta R) since its approval by the FDA in 2011. Benlysta is the first drug approved by the FDA for
SLE in 56 years. All future trials for new drugs for SLE have failed since 2011, a disappointing result for
Dr. Neuwelt and all lupus researchers. However, Saphnelo (Anifrolumab) broke this trend and was
published in the New England Journal of Medicine and received FDA approval in 2021. Dr. Neuwelt
participated in this clinical trial during the Double-blind Phase and the Open Label Extension with
approximately 20 patients.
Dr. Neuwelt also participated in subcutaneous Belimumab trials and ongoing Belimumab plus
standard-of-care treatment in Lupus Nephritis. In 2018 a trial began of Belimumab plus Rituximab
with the primary endpoint being relative remission in SLE.
In January of 2014 Dr. Neuwelt became the first Purple Ribbon Honoree for Outstanding Commitment
to Lupus Treatment and Research from the Lupus Foundation of Northern California.
In April of 2018 Dr. Neuwelt received the Lupus Advocate Award by the Lupus Awareness Project in
Northern California.
Dr. Neuwelt, in addition to his interest in research, continues to see patients in his private practice
and has not lost his passion for diagnosing and treating a complicated lupus patient.
St. Mary’s Medical Center, San Francisco, CA
Director of East Bay Rheumatology Research Institute
San Leandro, CA
Dr. Neuwelt has been challenged and fascinated by SLE since 1973 during his third year of medical school. This challenge and interest has persisted throughout his 43 years in clinical private practice which began in 1979.
His original publications involve an observational series and case reports of severe Neuropsychiatric Lupus (NPSLE), including progressive multifocal leukoencephalopathy mimicking NPSLE, and three treatment studies of Severe NPSLE with Cyclophosphamide, Rituximab, and plasmapheresis.
Dr. Neuwelt has extensive experience in B cell-depleting and modulating therapy in SLE, beginning
with cyclophosphamide in 1980, Rituximab in 2002 (second author of negative EXPLORER trial,
Ocrelizumab, Epratuzumab and Tabalumab. He has started over 200 patients on Belimumab
(Benlysta R) since its approval by the FDA in 2011. Benlysta is the first drug approved by the FDA for
SLE in 56 years. All future trials for new drugs for SLE have failed since 2011, a disappointing result for
Dr. Neuwelt and all lupus researchers. However, Saphnelo (Anifrolumab) broke this trend and was
published in the New England Journal of Medicine and received FDA approval in 2021. Dr. Neuwelt
participated in this clinical trial during the Double-blind Phase and the Open Label Extension with
approximately 20 patients.
Dr. Neuwelt also participated in subcutaneous Belimumab trials and ongoing Belimumab plus
standard-of-care treatment in Lupus Nephritis. In 2018 a trial began of Belimumab plus Rituximab
with the primary endpoint being relative remission in SLE.
In January of 2014 Dr. Neuwelt became the first Purple Ribbon Honoree for Outstanding Commitment
to Lupus Treatment and Research from the Lupus Foundation of Northern California.
In April of 2018 Dr. Neuwelt received the Lupus Advocate Award by the Lupus Awareness Project in
Northern California.
Dr. Neuwelt, in addition to his interest in research, continues to see patients in his private practice
and has not lost his passion for diagnosing and treating a complicated lupus patient.
Session 2: Keynote by Dr. Elizabeth Clayton
University of Maryland Shore Regional Health - Dorchester/Easton
University of Maryland Medical System, Easton, MD
Elizabeth S. Clayton, MD is a rheumatologist and managing partner of Rheumatology Associates of the DelMarVA.
Elizabeth S. Clayton, MD, is a Rheumatologist with University of Maryland Shore Regional Health - Dorchester/Easton, University of Maryland Medical System in Easton, Maryland.
Dr. Clayton received her medical degree from University of Maryland School of Medicine in Baltimore, Maryland, and completed her residency at University of Maryland Medical Center, also in Baltimore. She served her fellowship at the University of Maryland School of Medicine.
With board certifications in rheumatology and internal medicine, her clinical expertise is in general rheumatology. She is a fellow of American College of Rheumatology and has publications in Current Osteoporosis Reports, Current Opinion in Rheumatology, and British Journal of Surgery.
University of Maryland Medical System, Easton, MD
Elizabeth S. Clayton, MD is a rheumatologist and managing partner of Rheumatology Associates of the DelMarVA.
Elizabeth S. Clayton, MD, is a Rheumatologist with University of Maryland Shore Regional Health - Dorchester/Easton, University of Maryland Medical System in Easton, Maryland.
Dr. Clayton received her medical degree from University of Maryland School of Medicine in Baltimore, Maryland, and completed her residency at University of Maryland Medical Center, also in Baltimore. She served her fellowship at the University of Maryland School of Medicine.
With board certifications in rheumatology and internal medicine, her clinical expertise is in general rheumatology. She is a fellow of American College of Rheumatology and has publications in Current Osteoporosis Reports, Current Opinion in Rheumatology, and British Journal of Surgery.
Registration
Sponsored by:
|
|
|
